Special Issue "Treatments for Non-Small Cell Lung Cancer: The Multiple Options for Precision Medicine"
Deadline for manuscript submissions: 31 October 2021.
Interests: lung cancer; gastro-intestinal cancer; phase 1 trials; immunotherapy; targeted therapy
Lung cancer is one of the most aggressive cancers, with 1,796,1442 estimated deaths in 2020 worldwide. During the same time, 2,206,771 lung cancers were diagnosed, the majority of them with advanced disease. A multidisciplinary approach, supported by a broad therapeutic armamentarium including surgery, radiotherapy, and systemic treatments contributed to the recent advances that we have seen the past few years. Progress will also come through new techniques for the early detection of lung cancer (e.g., low-dose CT-scan).
Overall, the discovery of new anticancer drugs was prompted in part by the identification of predictive biomarkers, but has also been fostered by innovative designs (master protocols, umbrella and basket trials) for early-phase clinical trials. We can affirm that lung cancers are one of the best examples of what precision medicine can do.
In this Special Issue, we wish to collect original research and review articles addressing all innovations dedicated to lung cancers, screening to detect early stages, treatments for localized or oligometastatic disease, and certainly biomarkers, immune checkpoint inhibitors, targeted therapies, and antibody–drug conjugates.
Prof. Dr. Jaafar Bennouna
Dr. Elvire Pons-Tostivint
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- lung cancer
- targeted therapies
- antibody–drug conjugates
- neo-adjuvant treatment
- loco-regional treatments